|
|
|
|
|
Sample Preparation and Post-separation Analysis
| Searching in 'SWISS-2DPAGE' for entry matching: IGHG_HUMAN |
SWISS-2DPAGE: IGHG_HUMAN
IGHG_HUMAN:
Nice View - a user-friendly view of this entry
ID IGHG_HUMAN; STANDARD; 2DG.
AC P99006;
DT 01-AUG-1993, integrated into SWISS-2DPAGE (release 0).
DT 01-DEC-2000, 2D annotation version 1.
DT 01-DEC-2000, general annotation version 7.
DE Immunoglobulin heavy chain gamma.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini;
OC Hominidae; Homo.
OX NCBI_TaxID=9606;
MT CSF_HUMAN, PLASMA_HUMAN.
IM CSF_HUMAN, PLASMA_HUMAN.
RN [1]
RP MAPPING ON GEL.
RX MEDLINE=78094420; PubMed=271964; [NCBI, Expasy, EBI, Israel, Japan]
RA Anderson N.L., Anderson N.G.;
RT ''''''High resolution two-dimensional electrophoresis of human plasma proteins'';'';'';
RL Proc. Natl. Acad. Sci. U.S.A. 74(1):5421-5425(1977).
RN [2]
RP MAPPING ON GEL.
RX MEDLINE=96007934; PubMed=7498157; [NCBI, Expasy, EBI, Israel, Japan]
RA Sanchez J.-C., Appel R.D., Golaz O.G., Pasquali C., Ravier F., Bairoch
RA A., Hochstrasser D.F.;
RT ''''''Inside SWISS-2DPAGE database'';'';'';
RL Electrophoresis 16(1):1131-1151(1995).
2D -!- MASTER: CSF_HUMAN;
2D -!- PI/MW: SPOT 2D-000BX0=7.17/55193;
2D -!- PI/MW: SPOT 2D-000BX3=7.04/54913;
2D -!- PI/MW: SPOT 2D-000BX4=7.33/55475;
2D -!- PI/MW: SPOT 2D-000BX5=6.91/54773;
2D -!- PI/MW: SPOT 2D-000BXC=6.76/54495;
2D -!- PI/MW: SPOT 2D-000BXF=6.57/54080;
2D -!- PI/MW: SPOT 2D-000BXX=6.27/53260;
2D -!- PI/MW: SPOT 2D-000BXY=6.31/53260;
2D -!- PI/MW: SPOT 2D-000BY0=6.83/51921;
2D -!- PI/MW: SPOT 2D-000BY1=7.49/52453;
2D -!- PI/MW: SPOT 2D-000BY5=7.03/51789;
2D -!- PI/MW: SPOT 2D-000BY6=7.18/51789;
2D -!- PI/MW: SPOT 2D-000BY7=7.32/51921;
2D -!- PI/MW: SPOT 2D-000BY8=7.70/51657;
2D -!- PI/MW: SPOT 2D-000BY9=7.99/51921;
2D -!- PI/MW: SPOT 2D-000BYA=8.10/52990;
2D -!- PI/MW: SPOT 2D-000BYB=8.27/52186;
2D -!- PI/MW: SPOT 2D-000BYD=6.36/52990;
2D -!- PI/MW: SPOT 2D-000BYE=6.41/52186;
2D -!- PI/MW: SPOT 2D-000BYG=6.51/51921;
2D -!- PI/MW: SPOT 2D-000BYH=6.90/51657;
2D -!- PI/MW: SPOT 2D-000BYJ=6.24/52319;
2D -!- PI/MW: SPOT 2D-000BYK=6.45/52319;
2D -!- PI/MW: SPOT 2D-000BYL=6.61/51657;
2D -!- PI/MW: SPOT 2D-000BYO=6.35/51921;
2D -!- PI/MW: SPOT 2D-000BZ1=6.31/51789;
2D -!- MAPPING: MATCHING WITH THE PLASMA MASTER GEL [2].
2D -!- MASTER: PLASMA_HUMAN;
2D -!- PI/MW: SPOT 2D-0004AE=6.80/112014;
2D -!- PI/MW: SPOT 2D-0004AL=6.66/112014;
2D -!- PI/MW: SPOT 2D-0004AM=6.59/109656;
2D -!- PI/MW: SPOT 2D-0004AN=7.00/108112;
2D -!- PI/MW: SPOT 2D-0004AO=7.04/108882;
2D -!- PI/MW: SPOT 2D-0004AP=7.14/108882;
2D -!- PI/MW: SPOT 2D-0004AQ=7.35/109656;
2D -!- PI/MW: SPOT 2D-0004AT=6.86/110437;
2D -!- PI/MW: SPOT 2D-0004AU=6.95/110437;
2D -!- PI/MW: SPOT 2D-0004AV=7.51/108882;
2D -!- PI/MW: SPOT 2D-0004AZ=6.72/109656;
2D -!- PI/MW: SPOT 2D-0004B0=7.74/107348;
2D -!- PI/MW: SPOT 2D-0004BA=6.53/105837;
2D -!- PI/MW: SPOT 2D-0004BB=6.66/105837;
2D -!- PI/MW: SPOT 2D-0004BD=6.51/105837;
2D -!- PI/MW: SPOT 2D-0004BE=6.85/105837;
2D -!- PI/MW: SPOT 2D-0004BF=7.92/100712;
2D -!- PI/MW: SPOT 2D-0004BG=6.60/103609;
2D -!- PI/MW: SPOT 2D-0004BH=6.78/105089;
2D -!- PI/MW: SPOT 2D-0004BI=6.94/103609;
2D -!- PI/MW: SPOT 2D-0004BK=6.73/105089;
2D -!- PI/MW: SPOT 2D-0004BN=7.36/100712;
2D -!- PI/MW: SPOT 2D-0004BO=7.04/100000;
2D -!- PI/MW: SPOT 2D-0004BS=6.67/101428;
2D -!- PI/MW: SPOT 2D-0004BT=6.73/101428;
2D -!- PI/MW: SPOT 2D-0004BU=6.78/101428;
2D -!- PI/MW: SPOT 2D-0004BV=6.85/100712;
2D -!- PI/MW: SPOT 2D-0004BW=7.17/99619;
2D -!- PI/MW: SPOT 2D-0004BX=7.53/98862;
2D -!- PI/MW: SPOT 2D-0004C0=7.74/99240;
2D -!- PI/MW: SPOT 2D-0004CC=6.94/98862;
2D -!- PI/MW: SPOT 2D-0004D0=7.36/96995;
2D -!- PI/MW: SPOT 2D-0004D6=7.04/96258;
2D -!- PI/MW: SPOT 2D-0004D7=7.18/96626;
2D -!- PI/MW: SPOT 2D-0004D8=6.94/96258;
2D -!- PI/MW: SPOT 2D-0004S6=6.55/54804;
2D -!- PI/MW: SPOT 2D-0004SE=6.86/54655;
2D -!- PI/MW: SPOT 2D-0004SK=6.98/54359;
2D -!- PI/MW: SPOT 2D-0004SL=7.15/54507;
2D -!- PI/MW: SPOT 2D-0004SM=7.68/54507;
2D -!- PI/MW: SPOT 2D-0004SP=7.45/54507;
2D -!- PI/MW: SPOT 2D-0004ST=7.93/54507;
2D -!- PI/MW: SPOT 2D-0004SU=8.33/54804;
2D -!- PI/MW: SPOT 2D-0004SV=6.68/54507;
2D -!- PI/MW: SPOT 2D-0004SW=8.08/54507;
2D -!- PI/MW: SPOT 2D-0004SX=8.23/54655;
2D -!- PI/MW: SPOT 2D-0004T2=6.76/54359;
2D -!- PI/MW: SPOT 2D-0004TV=6.36/53336;
2D -!- PI/MW: SPOT 2D-0004U2=6.28/53336;
2D -!- PI/MW: SPOT 2D-0004U7=6.32/53191;
2D -!- PI/MW: SPOT 2D-0004UD=7.50/51068;
2D -!- PI/MW: SPOT 2D-0004UE=7.71/51347;
2D -!- PI/MW: SPOT 2D-0004UJ=6.15/52617;
2D -!- PI/MW: SPOT 2D-0004UK=6.46/52617;
2D -!- PI/MW: SPOT 2D-0004UL=6.52/52617;
2D -!- PI/MW: SPOT 2D-0004UM=6.86/50930;
2D -!- PI/MW: SPOT 2D-0004UN=7.17/51068;
2D -!- PI/MW: SPOT 2D-0004UO=8.10/52190;
2D -!- PI/MW: SPOT 2D-0004UU=6.24/52617;
2D -!- PI/MW: SPOT 2D-0004UV=6.43/51486;
2D -!- PI/MW: SPOT 2D-0004UW=6.49/51207;
2D -!- PI/MW: SPOT 2D-0004UX=7.99/51207;
2D -!- PI/MW: SPOT 2D-0004UY=8.35/51486;
2D -!- PI/MW: SPOT 2D-0004UZ=8.63/51626;
2D -!- PI/MW: SPOT 2D-0004V0=8.83/51767;
2D -!- PI/MW: SPOT 2D-0004V1=9.02/51907;
2D -!- PI/MW: SPOT 2D-0004V4=6.28/51767;
2D -!- PI/MW: SPOT 2D-0004V5=6.35/52474;
2D -!- PI/MW: SPOT 2D-0004V6=6.41/51486;
2D -!- PI/MW: SPOT 2D-0004V7=6.68/51068;
2D -!- PI/MW: SPOT 2D-0004V8=6.99/50930;
2D -!- PI/MW: SPOT 2D-0004V9=8.24/51207;
2D -!- PI/MW: SPOT 2D-0004VA=8.54/51626;
2D -!- PI/MW: SPOT 2D-0004VD=6.54/51207;
2D -!- PI/MW: SPOT 2D-0004VF=6.76/50792;
2D -!- PI/MW: SPOT 2D-0004VI=6.32/51626;
2D -!- PI/MW: SPOT 2D-0004VL=6.15/51767;
2D -!- PI/MW: SPOT 2D-0004VM=6.24/51486;
2D -!- PI/MW: SPOT 2D-0004VO=6.36/51207;
2D -!- PI/MW: SPOT 2D-0004WE=6.33/50654;
2D -!- NORMAL LEVEL: 8000-18000 MG/L.
2D -!- PATHOLOGICAL LEVEL: DECREASED DURING ANTIBODY DEFICIENCY SYNDROME;
2D INCREASED DURING CHRONIC INFECTIONS, LIVER DISEASES AND IGA MYELOMA.
2D -!- MAPPING: IMMUNOBLOTTING [1].
CC ---------------------------------------------------------------------------
CC This SWISS-2DPAGE entry is copyright the Swiss Institute of Bioinformatics.
CC There are no restrictions on its use by non-profit institutions as long as
CC its content is in no way modified and this statement is not removed.
CC Usage by and for commercial entities requires a license agreement (See
CC http://world-2dpage.expasy.org/swiss-2dpage/docs/license.html or send email from legal@sib.swiss).
CC ---------------------------------------------------------------------------
//
The following 2-D maps are available for this protein:
|
Cerebrospinal Fluid
 |
Plasma
 |
|---|
SWISS-2DPAGE (search AC)
|
